MDT-AP-3209
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 10.32
- os_event
- false
- age_years
- 9.25
- sex
- M
- fusion
- other ZFTA
- new_clusters
- C6
- umap1_2d
- 3.063217003
- umap2_2d
- 6.111669957
- umap1_3d
- 1.970119401
- umap2_3d
- -0.388146332
- umap3_3d
- -4.282740541
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.320
- G2M_CHECKPOINT+0.180
- E2F_TARGETS+0.160
- SPERMATOGENESIS+0.130
- HEME_METABOLISM+0.090
- MITOTIC_SPINDLE+0.040
- PI3K_AKT_MTOR_SIGNALING+0.040
- UNFOLDED_PROTEIN_RESPONSE+0.030
- DNA_REPAIR+0.010
- FATTY_ACID_METABOLISM-0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- MYC_TARGETS_V2-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- ANGIOGENESIS-0.340
- INTERFERON_GAMMA_RESPONSE-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- MYOGENESIS-0.300
- APICAL_SURFACE-0.290
- INFLAMMATORY_RESPONSE-0.280
- P53_PATHWAY-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2992 | Med | Medulloblastoma | 0.888 |
| 2 | SJEPD030097_D2.RNA-Seq | EPN | Spinal EPN | 0.882 |
| 3 | BS_J8G4SH4Z | Med | Medulloblastoma | 0.872 |
| 4 | BS_HTEPAKCM | medulloblastoma | — | 0.870 |
| 5 | BS_5PJCHF6V | medulloblastoma | — | 0.866 |
| 6 | BS_2SFTWNVE | medulloblastoma | — | 0.863 |
| 7 | BS_KN92S7YQ | medulloblastoma | — | 0.856 |
| 8 | SRR657325 | GTEX | — | 0.853 |
| 9 | MDT-AP-3207 | Med | Medulloblastoma | 0.851 |
| 10 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |